Urogen Pharma Ltd
URGN21.390USD
+0.040+0.19%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.00BCap. mercado
PérdidaP/E TTM
Más Datos de Urogen Pharma Ltd Compañía
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Información de Urogen Pharma Ltd
Símbolo de cotizaciónURGN
Nombre de la empresaUrogen Pharma Ltd
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoBarrett (Elizabeth A)
Número de empleados235
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección9 Ha'ta'asiya St
CiudadRA'ANANA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal4365007
Teléfono97297707601
Sitio Webhttps://www.urogen.com/
Símbolo de cotizaciónURGN
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoBarrett (Elizabeth A)
Ejecutivos de Urogen Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
Otro
64.52%
Accionistas
Accionistas
Proporción
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
Otro
64.52%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
29.37%
Research Firm
22.98%
Investment Advisor
22.01%
Investment Advisor/Hedge Fund
19.50%
Insurance Company
4.14%
Individual Investor
2.09%
Corporation
1.79%
Private Equity
1.47%
Bank and Trust
0.25%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
321
48.31M
103.21%
-13.86M
2025Q3
311
45.66M
97.55%
-6.58M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RTW Investments L.P.
4.54M
9.71%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
4.22M
9.01%
+1.88M
+80.79%
Sep 30, 2025
TD Securities, Inc.
3.19M
6.82%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.46M
5.25%
+983.01K
+66.65%
Sep 30, 2025
Jefferies LLC
2.20M
4.7%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.58%
+33.75K
+1.60%
Sep 30, 2025
SilverArc Capital Management, LLC
1.58M
3.37%
-445.20K
-22.01%
Sep 30, 2025
Millennium Management LLC
1.47M
3.14%
+874.71K
+147.25%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.32M
2.82%
--
--
Jan 31, 2025
Acorn Capital Advisors, LLC
1.26M
2.69%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ARK Israel Innovative Technology ETF
2.09%
Tema Oncology ETF
1.92%
ALPS Medical Breakthroughs ETF
0.39%
Hypatia Women CEO ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Micro-Cap ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.07%
Ver más
ARK Israel Innovative Technology ETF
Proporción2.09%
Tema Oncology ETF
Proporción1.92%
ALPS Medical Breakthroughs ETF
Proporción0.39%
Hypatia Women CEO ETF
Proporción0.28%
ProShares Ultra Nasdaq Biotechnology
Proporción0.16%
iShares Micro-Cap ETF
Proporción0.15%
Fidelity Enhanced Small Cap ETF
Proporción0.11%
Vanguard US Momentum Factor ETF
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.09%
iShares Biotechnology ETF
Proporción0.07%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
